SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

Materials and resources for healthcare professionals:

Mutation Card

See all indicated mutations for SYMDEKO.


Clinical Brochure

Review information about efficacy, safety, DDIs, and dosing.


Initiation Guide

Review considerations for initiating SYMDEKO.


F508del Homozygous Clinical Trial Overview Brochure

Review information about patients with CF who are homozygous for the F508del mutation.

Clinical Results

Materials for you to share with your patients:

SYMDEKO Brochure

Help patients learn how SYMDEKO works, and see study details, results, and possible side effects.